DoD Prostate Cancer Population Science Impact Award

archived

The PCRP Population Science Impact Award (PSIA) mechanism was first offered as the Population-Based Idea Development Award in FY09 and Population-Based Research Award in FY10 and FY11. In total, 62 applications have been received, and 4 have been recommended for funding. The Population Science Impact Award mechanism supports high-impact, population science approaches to prostate cancer research. Applications should clearly demonstrate the potential of the study to contribute significantly to the elimination of death from prostate cancer and/or enhancing the well-being of men experiencing the impact of the disease. As such, studies should address one of the PCRP overarching challenges, or, alternatively, justify the study as addressing another critical area in prostate cancer research. In addition, studies are expected to address one or more of the PCRP focus areas; for the PSIA, projects focused on the following are particularly encouraged: biomarkers, especially those relevant to aggressive disease; genetics/ genomics; therapy and predictors of response or resistance; and survivorship and palliative care. Studies that, in whole or in part, address disparities in prostate cancer incidence, morbidity, or mortality, are also encouraged. The overall goal of this award is to generate data and/or tools that can only be achieved from the perspective of systematic studies focused on specific populations of individuals, rather than specific individuals. Such studies will be built upon the logic, concepts, and methods of one or more population sciences including but not limited to: • Epidemiology • Surveillance • Health services research • Outcomes research • Behavioral science • Social science • Dissemination research The outcomes for research supported through this award mechanism will have the potential for substantial impact for men with or at risk for prostate cancer within, for example, epidemiologic cohorts, defined communities, or health systems. Applications may propose retrospective, prospective, case control, cohort, or other population science study designs (including the use of biospecimens and data from established retrospective databases), provided the proposed sample is of sufficient size to demonstrate statistical significance. The study should address a well-developed hypothesis that is conceptually sound and specific for prostate cancer. The statistical expertise of the study team should be clearly described and evident in the study plan. Applicants are expected to provide documentation demonstrating access to, and ability to recruit as applicable, the appropriate population(s), patient samples, datasets in numbers sufficient to achieve statistical significance. Research involving human subject use is permitted under this funding opportunity, but is restricted to studies without clinical trials; however, correlative studies with populations from existing clinical trials, are allowed. For definitions and other information on clinical trials and clinical research overall, a Human Subject Resource Document is provided on the CDMRP eReceipt System at https://cdmrp.org/Program_Announcements_and_Forms/. All investigators applying to FY13 PCRP funding opportunities are encouraged to consider leveraging resources available through the PCRP-funded Prostate Cancer Biorepository Network (PCBN) (http://www.prostatebiorepository.org) and/or the North Carolina – Louisiana Prostate Cancer Project (PCaP) (http://www.ncla-pcap.org), if retrospectively collected human anatomical substances or correlated data are relevant to the proposed studies. The CDMRP intends that data and research resources generated under awards funded by this Program Announcement/Funding Opportunity be made available to the research community (which includes both scientific and consumer advocacy communities) and to the public at large. For additional guidance, refer to the General Application Instructions, Appendix 4, Section K.

High